Last updated: November 2, 2026
ACZONE is a topical dapsone product for acne vulgaris, marketed in the United States by Almirall after its acquisition of Allergan’s U.S. dermatology business. The product has two strengths: 5% gel administered twice daily and 7.5% gel administered once daily. ACZONE remains commercially relevant in prescription acne, but its financial profile has weakened because generic dapsone 5% gel entered the market and because acne treatment has become more competitive.
Product-level revenue is not separately reported by Almirall. The available financial record supports a trajectory of material commercial contribution before generic entry, followed by erosion in the U.S. dermatology portfolio after generic competition.
What is ACZONE and how does it work?
ACZONE contains dapsone, a sulfone antibiotic and anti-inflammatory agent. The gel is approved for the topical treatment of acne vulgaris in patients age 12 and older.
| Product |
Strength |
Dosing |
FDA indication |
| ACZONE Gel |
5% |
Apply twice daily |
Acne vulgaris |
| ACZONE Gel |
7.5% |
Apply once daily |
Acne vulgaris |
The 5% product was approved in 2008. The 7.5% once-daily product was approved in 2017. The once-daily formulation was intended to improve convenience and extend the branded product franchise beyond the original 5% formulation.
Dapsone has a differentiated mechanism relative to retinoids and benzoyl peroxide. Its anti-inflammatory properties support use in inflammatory acne, while its topical delivery limits systemic exposure compared with oral dapsone. The product label warns about methemoglobinemia and hemolytic anemia risks, particularly in patients with glucose-6-phosphate dehydrogenase deficiency. ACZONE should not be combined casually with other oxidizing or hematologic-risk treatments. (U.S. Food and Drug Administration, 2017)
Who owns and markets ACZONE?
Almirall is the current U.S. commercial owner following its 2019 acquisition of Allergan’s U.S. dermatology business.
| Date |
Corporate event |
Commercial consequence |
| 2008 |
FDA approves ACZONE 5% |
Branded dapsone gel enters the acne market |
| 2017 |
FDA approves ACZONE 7.5% |
Once-daily formulation expands the franchise |
| 2019 |
Almirall acquires Allergan’s U.S. dermatology business |
ACZONE moves into Almirall’s U.S. portfolio |
| 2020 onward |
Generic competition develops for dapsone 5% gel |
Pressure increases on price, prescriptions, and payer coverage |
The acquisition included ACZONE and other established dermatology products. Almirall paid approximately $550 million for the U.S. dermatology portfolio, including upfront consideration and related transaction components reported at the time. The transaction gave Almirall a larger U.S. commercial platform but also transferred exposure to products approaching or facing loss of exclusivity. (Almirall, 2019)
How much revenue has ACZONE generated?
Almirall does not report ACZONE revenue as a separate line item. Its financial disclosures aggregate products within the U.S. dermatology business and do not provide a complete annual sales history for ACZONE.
Historical Allergan disclosures indicate that ACZONE was a meaningful branded dermatology asset before generic entry. Industry estimates placed annual U.S. ACZONE sales in the low hundreds of millions of dollars near the product’s commercial peak. Those estimates are more reliable as an indication of scale than as audited product revenue.
The financial trajectory can be summarized as follows:
| Period |
Financial position |
Main driver |
| 2008-2016 |
Expansion phase |
Differentiated prescription acne product with limited direct generic competition |
| 2017-2019 |
Franchise extension |
Launch of 7.5% once-daily gel and continued branded promotion |
| 2019-2021 |
Portfolio transition |
Almirall acquisition and integration into U.S. dermatology |
| 2022 onward |
Erosion phase |
Generic dapsone 5% availability, payer substitution, and lower net pricing |
ACZONE’s economic value depended on branded reimbursement and physician prescribing rather than a large manufacturing barrier. Once a therapeutically substitutable generic became available, the product’s gross-to-net profile became more vulnerable. Rebates, preferred formulary placement, and pharmacy substitution can reduce branded revenue even when the branded product retains clinical recognition.
When did ACZONE lose exclusivity?
ACZONE did not lose all commercial protection on a single date. Exclusivity eroded in stages.
The most important event was generic availability for dapsone 5% gel. The 5% formulation was the older and more exposed strength. The 7.5% product has a different concentration and dosing schedule, but the two products compete within the same acne-treatment category.
The practical exclusivity timeline is:
| Exclusivity layer |
Status |
| FDA new-drug exclusivity for the original product |
Expired |
| 5% formulation patent protection |
No longer sufficient to prevent generic market entry |
| 7.5% formulation and related patent protection |
Potentially longer-lived than the 5% product, but subject to patent scope and validity |
| Trade name and physician familiarity |
Continues, but does not prevent generic substitution |
| Formulation know-how |
Provides limited protection where the generic product is pharmaceutically equivalent |
A precise commercial loss-of-exclusivity date must distinguish FDA exclusivity, patent expiration, ANDA approval, and actual generic launch. These events do not always occur on the same date. For ACZONE, generic market entry for the 5% product is the material commercial trigger.
What is the FDA and Orange Book status of ACZONE?
ACZONE is an FDA-approved small-molecule topical drug, not a biologic. It is therefore subject to the ANDA generic pathway rather than the biosimilar pathway.
The FDA Orange Book is the controlling public source for listed patents and approved therapeutic-equivalence information. ACZONE’s listed-product history has included formulation and drug-product patents associated with topical dapsone gel. The legal significance of each listing depends on whether the patent covers the active ingredient, formulation, dosage form, method of use, or a combination of those elements.
The regulatory position is:
| Regulatory issue |
ACZONE status |
| FDA approval |
Approved |
| Active ingredient |
Dapsone |
| Dosage form |
Topical gel |
| Drug class |
Small-molecule dermatology product |
| ANDA pathway |
Applicable |
| 505(b)(2) pathway |
Possible for differentiated topical products, but not the normal route for an equivalent generic |
| Biosimilar pathway |
Not applicable |
| Orange Book listing |
Relevant for approved product patents and generic certification |
The FDA label identifies ACZONE 5% and 7.5% as topical acne treatments. Generic dapsone gel products must meet applicable pharmaceutical equivalence and bioequivalence requirements under the ANDA framework. (U.S. Food and Drug Administration, 2023)
Which patents protect ACZONE?
ACZONE’s patent estate has relied more on drug-product and formulation protection than on composition-of-matter protection for a new chemical entity.
Formulation patents
The principal commercial value of ACZONE patents has been associated with:
- Dapsone gel formulations
- Stabilized topical compositions
- Concentration-specific products
- Vehicle and excipient combinations
- Manufacturing and consistency attributes
- Methods of treating acne with topical dapsone
Formulation patents are generally narrower than chemical composition patents. Their strength depends on whether the generic product practices the claimed formulation and whether the claims survive validity and infringement challenges.
Method-of-use patents
Method-of-use claims may cover treatment of acne with topical dapsone, specific patient populations, dosing schedules, or particular disease presentations. In an ANDA dispute, a generic applicant may submit a Paragraph IV certification asserting that a listed method-of-use patent is invalid, unenforceable, or not infringed.
Method-of-use protection is less effective when the generic can use a section viii statement and omit the patented indication or instruction from its labeling. Acne is the central commercial use for ACZONE, so the practical value of an indication carve-out depends on the scope of the remaining label and pharmacy substitution rules.
Patent-strength assessment
| Patent layer |
Relative strength |
Commercial impact |
| New chemical entity protection |
Low or unavailable at the current stage |
Does not block modern generic entry |
| 5% formulation protection |
Low after generic entry |
Main 5% product barrier has been breached |
| 7.5% formulation protection |
Moderate if claims remain in force and are commercially relevant |
May delay or complicate direct substitution |
| Method-of-use claims |
Low to moderate |
Vulnerable to labeling carve-outs |
| Trade dress and brand recognition |
Low legal exclusivity, moderate commercial value |
Does not prevent pharmacy substitution |
| Manufacturing know-how |
Moderate operational value |
Usually not a complete market-entry barrier |
Were there Paragraph IV challenges to ACZONE?
Generic applicants seeking approval before expiration of listed patents can submit Paragraph IV certifications. Such certifications can trigger patent litigation and, under the Hatch-Waxman framework, a potential 30-month stay of FDA approval if the brand owner files suit within the statutory period.
The ACZONE generic-risk pattern is consistent with other established topical dermatology products:
- An ANDA applicant identifies listed ACZONE patents.
- The applicant submits a Paragraph IV certification for patents it challenges.
- The brand owner may file an infringement action.
- FDA approval may be delayed by the statutory stay.
- The parties may settle, or the generic may launch after litigation or patent expiration.
The principal commercial result was generic availability for dapsone 5% gel. Public financial reporting does not provide a single consolidated ACZONE litigation outcome that explains every listed patent and every generic applicant. The market should therefore be analyzed by product strength and actual generic availability, not only by the existence of Orange Book patents.
What generic entry risks exist for ACZONE?
The most immediate risk is substitution of generic dapsone 5% gel for branded ACZONE 5%. The main risks are:
- Lower net selling price
- Formulary exclusion or non-preferred status
- Automatic pharmacy substitution where permitted
- Reduced physician sampling and promotion
- Lower patient willingness to pay branded copay differentials
- Generic competition from multiple ANDA holders
- Declining prescription volume after the initial generic launch
- Higher rebates required to retain managed-care access
The 7.5% product has some defensive value because it offers once-daily dosing and may have separate formulation claims. That protection is limited. A branded concentration advantage does not guarantee durable exclusivity if physicians can prescribe a lower-cost equivalent strength or use another topical acne therapy.
How does ACZONE compare with competing acne drugs?
ACZONE operates in a crowded prescription acne market.
| Product or class |
Active ingredient |
Competitive position |
| Generic dapsone gel |
Dapsone |
Direct substitute for ACZONE 5% |
| Differin and generic adapalene |
Adapalene |
Low-cost retinoid with broad acne use |
| Tretinoin products |
Tretinoin |
Established topical retinoid class |
| Benzoyl peroxide products |
Benzoyl peroxide |
Widely available, low-cost antibacterial and keratolytic option |
| Clindamycin combinations |
Clindamycin plus benzoyl peroxide or retinoid |
Common for inflammatory acne, but antibiotic stewardship limits duration |
| Winlevi |
Clascoterone |
Branded topical androgen-receptor inhibitor |
| Arazlo |
Tazarotene |
Branded topical retinoid |
| Zilxi |
Minocycline foam |
Branded topical antibiotic |
| Epsolay |
Benzoyl peroxide foam |
Branded formulation with premium pricing |
ACZONE’s advantages are anti-inflammatory activity, topical administration, and a non-retinoid profile. Its disadvantages are generic substitution, safety monitoring concerns related to dapsone, and competition from lower-cost topical therapies.
What is the competitive landscape for Almirall?
Almirall’s U.S. dermatology strategy includes both mature products and newer branded assets. ACZONE is commercially less attractive than a protected product with a large untreated population because its core 5% formulation is exposed to generic competition.
The competitive landscape has three tiers:
Low-cost generic therapies
Generic adapalene, tretinoin, benzoyl peroxide, clindamycin combinations, and dapsone gel compete on price and payer access. These products constrain ACZONE’s ability to sustain premium pricing.
Branded topical therapies
Winlevi, Arazlo, Zilxi, and Epsolay compete for dermatology visits and formulary budgets. Branded competitors can preserve premium pricing through differentiated mechanisms, vehicles, dosing, or marketing claims.
Oral treatments
Oral antibiotics, isotretinoin, and hormonal therapies compete for patients with moderate-to-severe or refractory acne. ACZONE is more relevant in mild-to-moderate inflammatory acne and for patients seeking a topical, non-retinoid option.
What licensing and transaction activity affects ACZONE?
The most important transaction was Almirall’s acquisition of Allergan’s U.S. dermatology business in 2019. That transaction transferred ACZONE and other dermatology brands into Almirall’s portfolio. It was an asset acquisition rather than a new licensing arrangement for the active ingredient.
The transaction’s investment case depended on portfolio cash flow, commercial synergies, and Almirall’s ability to support U.S. dermatology products. Generic erosion reduces the standalone value of ACZONE but does not eliminate its value as part of a broader portfolio, particularly where the product retains physician awareness and residual branded demand.
What manufacturing and intellectual-property barriers remain?
Manufacturing ACZONE is less difficult than developing a novel biologic, but topical semisolid products create technical requirements. A competing manufacturer must control:
- Dapsone particle size and dispersion
- Gel uniformity
- Stability and impurity profile
- Container compatibility
- Microbial quality
- Dose delivery from the package
- In vitro release and permeation characteristics
- Scale-up consistency
These factors can raise development costs and create regulatory risk. They do not create a durable barrier comparable to a complex biologic manufacturing process. Once a generic is approved, manufacturing know-how generally supports cost control rather than market exclusivity.
What is the likely financial trajectory for ACZONE?
ACZONE is best classified as a mature branded dermatology asset in post-generic erosion.
The likely trajectory is:
- Continued decline in 5% branded prescriptions after generic substitution.
- Lower net price and reduced payer coverage for the branded product.
- Residual demand from patients and physicians who prefer the branded product.
- Some protection from the 7.5% once-daily formulation.
- Limited ability to restore historical revenue without a new indication, improved formulation, or materially differentiated clinical data.
- Declining contribution to Almirall’s U.S. dermatology growth relative to newer products.
ACZONE’s residual value is more likely to come from cash flow, brand recognition, and portfolio cross-selling than from sustained exclusivity. Investors evaluating Almirall should treat ACZONE as a declining or mature revenue contributor, not as a principal growth driver.
Key Takeaways
- ACZONE is topical dapsone gel approved for acne vulgaris in 5% and 7.5% strengths.
- Almirall acquired the U.S. rights and commercial business from Allergan in 2019.
- Product-level ACZONE revenue is not separately disclosed by Almirall.
- Historical sales reached a commercially meaningful level before generic competition.
- Generic dapsone 5% gel is the main source of revenue and pricing pressure.
- The 7.5% once-daily product provides some differentiation but does not eliminate substitution risk.
- ACZONE is governed by the ANDA pathway, not the biosimilar pathway.
- Formulation and method-of-use patents provide narrower protection than a new chemical entity patent.
- The product faces direct competition from generic dapsone, adapalene, tretinoin, benzoyl peroxide, clindamycin combinations, Winlevi, Arazlo, Zilxi, and Epsolay.
- ACZONE should be valued as a mature dermatology asset with declining exclusivity and residual branded cash flow.
FAQs About ACZONE Market Dynamics and Patent Risk
Is ACZONE still sold in the United States?
Yes. ACZONE remains an FDA-approved prescription topical dapsone product, although commercial availability and payer coverage can vary by strength, distributor, and formulary status.
Is generic ACZONE the same as generic dapsone gel?
Generic dapsone gel is intended to be therapeutically equivalent to the corresponding approved ACZONE product when the FDA assigns an equivalent rating. The approved strength, formulation, labeling, and substitution rules determine the practical relationship.
Does ACZONE have biosimilar competition?
No. ACZONE contains dapsone, a small molecule. Competition proceeds through the generic-drug pathway rather than the biosimilar pathway.
Can a patient substitute ACZONE 7.5% for ACZONE 5%?
No automatic substitution should be assumed between the two strengths. They have different concentrations and dosing schedules, and substitution depends on the prescription, product equivalence, state law, and pharmacy practice.
Is ACZONE a growth product for Almirall?
ACZONE is more accurately characterized as a mature portfolio product. Its growth potential is constrained by generic dapsone competition, crowded acne treatment options, and the absence of separately reported product-level sales growth.
References
-
Almirall, S.A. (2019). Almirall to acquire Allergan’s U.S. dermatology business. Almirall corporate announcement.
-
Almirall, S.A. (2023). Annual report 2023. Barcelona, Spain: Almirall.
-
Allergan plc. (2018). Annual report 2018. Dublin, Ireland: Allergan.
-
U.S. Food and Drug Administration. (2017). ACZONE (dapsone) gel, 7.5% prescribing information. Silver Spring, MD: FDA.
-
U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: FDA.
-
U.S. Food and Drug Administration. (2023). Approved drug products and generic drug approval information. Silver Spring, MD: FDA.
